 Home > Medical News > Medicines Company News > Innovent Biologics PD-1/IL-2 bispecific antibody fusion protein IBI363 completed the first clinical patient administration in Australia

Innovent Biologics PD-1/IL-2 bispecific antibody fusion protein IBI363 completed the first clinical patient administration in Australia

 Last Update: 2022-09-24
 Source: Internet
 Author: User

Tags

jak inhibitor drugs

abundant protein body

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Cinda Biopharmaceutical Group (HKEx Stock Code: 01801), a biopharmaceutical company dedicated to the research and development, production and sales of innovative drugs in the field of oncology, self-immunity, metabolism, ophthalmology and other major diseases, Today announced the completion of its self-developed recombinant anti-programmed death receptor 1 (PD-1) antibody fusion interleukin 2 (IL-2) bispecific molecule (R&D code: IBI363) in a Phase I clinical trial in Australia for the treatment of advanced solid tumors or

The study (NCT05290597) was an open-label, multicenter phase I study whose primary objective was to evaluate the safety, tolerability, and initial efficacy of IBI363 in subjects with advanced solid tumors or lymphomas, and to determine the phase II recommended dose (RP2D).

Interleukin-2 (IL-2) is a cytokine secreted by CD4+ T cells mainly activated by antigens, which plays an important role

IBI363 is a potential First-in-Class new drug independently developed by Innovent Biologics, with the active ingredient of PD-1/IL-2 bispecific antibody fusion protein

Dr.

Interleukin-2 (IL-2) is a cytokine secreted by CD4+ T cells mainly activated by antigens, which plays an important role

IBI363 is a potential First-in-Class new drug independently developed by Innovent Biologics, with the active ingredient of PD-1/IL-2 bispecific antibody fusion protein

Dr.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.